RxDoctor Payments Data

Brunel Gomez de Tavarez, MD

Internal Medicine · Lakewood Ranch, FLNPI 1013352343

Payments from drug & device makers

$3,346in general payments, 2019–2025

Across 175 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$777
  • Pfizer$631
  • AbbVie$384
  • Corium, LLC$232
  • Exact Sciences$148
  • Astellas Pharma US Inc$144
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,346100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,346 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$164,393
Medicare patients
481
Services billed
1,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide102$129,462
OzempicSemaglutide55$62,336
FarxigaDapagliflozin Propanediol31$39,826
JardianceEmpagliflozin37$38,916
RybelsusSemaglutide20$38,771
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$36,457
EliquisApixaban24$32,391
VraylarCariprazine Hcl13$21,800
XareltoRivaroxaban11$17,143
MyrbetriqMirabegron18$11,377
Breo ElliptaFluticasone/Vilanterol12$8,261
SynthroidLevothyroxine Sodium71$7,160
Rosuvastatin Calcium348$3,813
Atorvastatin Calcium494$3,691
Estradiol49$3,172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$132$129,462102 claims
Novo NordiskOzempic, Rybelsus$777$101,10875 claims
GSKTrelegy Ellipta, Breo Ellipta$26$44,71759 claims
AstraZenecaFarxiga$98$39,82631 claims
PfizerEliquis, Paxlovid$631$33,82066 claims
AbbVieVraylar, Synthroid$384$28,96184 claims
Astellas Pharma US IncMyrbetriq$144$11,37718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lakewood Ranch

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →